# Fortis Malar (NSE: FORTISMLR) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/FORTISMLR · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹97 Cr, it ranks 2696th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.

Its return on equity was 12.0% in FY26. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹0 Cr (−100.0% year on year) and net profit ₹0 Cr (−96.4%), on a consolidated basis. Promoters held 62.71% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹97 Cr |
| ROE | 12.0% (FY26) |
| ROCE | 13.8% (FY26) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹0 Cr | −100.0% | ₹0 Cr | −96.4% | ₹0.08 |
| Q4 FY26 | ₹0 Cr | — | −₹0 Cr | −113.9% | −₹0.02 |
| Q3 FY26 | ₹0 Cr | — | ₹0 Cr | +100.0% | ₹0.01 |
| Q2 FY26 | ₹0 Cr | — | ₹0 Cr | −88.9% | ₹0.01 |
| Q1 FY26 | ₹0 Cr | — | ₹4 Cr | — | ₹2.22 |
| Q4 FY25 | — | — | ₹0 Cr | −99.3% | ₹0.19 |
| Q3 FY25 | — | — | ₹0 Cr | — | ₹0.00 |
| Q2 FY25 | — | — | ₹0 Cr | — | ₹0.05 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹0 Cr | ₹0 Cr |
| FY24 | ₹59 Cr | ₹45 Cr |
| FY23 | ₹86 Cr | −₹15 Cr |
| FY22 | ₹86 Cr | −₹8 Cr |
| FY21 | ₹69 Cr | −₹8 Cr |
| FY20 | ₹112 Cr | −₹9 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 62.71%
- Domestic institutions: 0.07%
- Non-institutions: 37.22%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Mercury Labs](https://app.pivotnow.in/stock/MERCURYLAB) | — | ₹102 Cr | — | — |
| [Vaishali Pharma](https://app.pivotnow.in/stock/VAISHALI) | ₹7.49 | ₹101 Cr | 124.8 | — |
| [Concord Drugs](https://app.pivotnow.in/stock/CONCORD) | — | ₹101 Cr | — | — |
| [Denis Chem Lab](https://app.pivotnow.in/stock/DENISCHEM) | — | ₹101 Cr | — | — |
| [Raaj Medisafe](https://app.pivotnow.in/stock/RAAJMEDI) | — | ₹97 Cr | — | — |
| [KHFM HOSPITALIT](https://app.pivotnow.in/stock/KHFM) | ₹40.90 | ₹95 Cr | — | — |

## Questions and answers

### What is the market cap of Fortis Malar?

Fortis Malar's market capitalisation is ₹97 Cr (₹97 Cr) at the 22 Oct 2026 close, ranking 2696th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Fortis Malar?

Return on equity was 12.0% in FY26 and return on capital employed was 13.8% in FY26 (consolidated figures).

### Is Fortis Malar a debt-free company?

Fortis Malar is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Fortis Malar's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Fortis Malar reported revenue of ₹0 Cr, −100.0% year on year, and net profit of ₹0 Cr, −96.4% year on year.

### What is the shareholding pattern of Fortis Malar?

As of 30 Jun 2026: promoters 62.71%, domestic institutions 0.07%, non-institutions 37.22%.

### Who are Fortis Malar's competitors?

The listed Pharma & Healthcare companies closest to Fortis Malar by market cap are Mercury Labs, Vaishali Pharma, Concord Drugs, Denis Chem Lab, Raaj Medisafe and KHFM HOSPITALIT.

### Is Fortis Malar a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Fortis Malar's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on FORTISMLR against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.